Personalizing
Cancer Treatment for Everyone

WEBINAR

Childhood Cancer
Precision in Pediatrics: Diagnosing and Curing Childhood Cancer

Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by  Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.

If you missed the webinar, you can still watch the recording here.

 

Ask our doctors your questions about cancer
Panel of Doctors Answer Your Questions About Cancer

Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar. 

Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio. 

Cancer Treatment Doctor
Bringing state-of-the-art precision cancer care Bringing state-of-the-art precision cancer care to rural communities

Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT. 

Dr. Belisario Arango covered the following topics:

Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients? 
Where is the future of cancer care going?

VIEW ALL ARTICLES

PRESS RELEASES

J.P. Morgan (JPM) Healthcare Conference Insights
J.P. Morgan (JPM) Healthcare Conference Insights from Massive Bio Co-founder and CEO, Selin Kurnaz

Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together. 

Happy Valentine's Day Savings
Happy Valentine's Day Offer

We continue to support you and your loved ones by sharing new savings. 

he American Turkish Society is pleased to announce the sixth class of
Massive Bio CEO chosen for 2017 Class of Young Society Leaders

The American Turkish Society is pleased to announce the sixth class of "Young Society Leaders," a group of 25 accomplished professionals with a demonstrated record of leadership ability and commitment to serve the U.S.-Turkish community at large.

Holiday Savings New Year 2018 for Cancer Patients
2018 New Year Holiday Savings

We are starting our New Year Holiday Savings early and ending it late!
 

VIEW ALL ARTICLES

IN THE NEWS

Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer
Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer

Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows.

Cancer Vaccine Works 'Startlingly Well' in Mouse Model
Cancer Vaccine Works 'Startlingly Well' in Mouse Model

An experimental cancer vaccine has demonstrated dramatic results in mice with many different cancer types and distant metastases and is now to be tested in patients with cancer.

 

Starving cancer cells of sugar -- does it work?
Starving cancer cells of sugar -- does it work?

Previous research have shown that rapidly dividing cancer cells require higher levels of sugar than healthy cells. This dependency on sugar distinguishes cancer cells from normal cells and is often used as a treatment option to kill cancer cells. In reality, the results have not been encouraging. Not all cancer cell types are sensitive to the removal of sugar, and even for the cancers that are sensitive, sugar depletion only slows down the rate of cancer progression. The pathways that sensitise cancer cells to sugar deprivation remains poorly understood.

 

Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years
Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years

They are among the most challenging prostate cancer patients to treat: about 150,000 men worldwide each year whose cancer is aggressive enough to defy standard hormonal therapy, but has not yet spread to the point where it can be seen on scans.

 

VIEW ALL ARTICLES

PUBLISHED RESEARCH

Considerations and Advancements of Precision Medicine in GI Cancers
Considerations and Advancements of Precision Medicine in GI Cancers

This activity is designed to inform physicians about the current availability and use of targeted therapies and precision medicine in gastric (GC) and other gastrointestinal (GI) cancers.

 

Oral Versus IV Oncolytics
Oral Versus IV Oncolytics

Here, we have oral drugs. How do these oral oncolytics compare to the parenteral drugs–the only drugs, really, when I was growing up in medicine–in terms of use and in terms of access?

 

Two widely used regimens for advanced-stage follicular lymphoma led to similar high rates of long-term survival, as reported in the Journal of Clinical Oncology.
Follicular Lymphoma Regimens Equivalent

Two widely used regimens for advanced-stage follicular lymphoma led to similar high rates of long-term survival, as reported in the Journal of Clinical Oncology.

 

Breast cancer control equivalent to 5 years
Extended AI Can Stop after 2 Years

Continuing adjuvant aromatase inhibitor (AI) therapy for 2 years beyond the current standard 5 years of treatment yielded the same level of recurrence prevention as continuing the treatment for an extra 5 years, according to a report at the San Antonio Breast Cancer Symposium.

 

VIEW ALL ARTICLES

NEWSLETTER

January 2018 Massive Bio Newsletter
J.P. Morgan Healthcare Conference Insights January 2018 Newsletter

Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. 

January 2018 Massive Bio Newsletter
J.P. Morgan Healthcare Conference Insights January 2018 Newsletter

Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. 

VIEW ALL ARTICLES
Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top